Altimmune: AdCOVID's Potential To Prevent Transmission May Be Key To Ending The Pandemic

Summary

• Biotechvalley Insights is upgrading ALT's rating to "Very Bullish" from a "Bullish" rating with a 12 month TP of US$52.
• Altimmune's (ALT) valuation is at a discount after the recent sell-off, and the fundamental picture has improved with more clarity around manufacturing.
• ALT has added new high-profile biotech investors on board, and institutional investors hold 75% of the float. This means the stock could potentially run 100-200% higher with a catalyst.
• AdCOVID has all the characteristics that WHO is looking for: sterilizing immunity (prevention of infection and transmission), safety, a single-dose administration, intranasal route of administration, and room temperature storage.
• The OWS vaccines do not prevent "transmission" and may not abate this pandemic. As such, COVID-19 may linger until the approval of an effective vaccine that can induce sterilizing immunity.

Source: Altimmune Website

I wrote about Altimmune (NASDAQ:ALT) 3 months ago and mentioned that there would be a better time to accumulate ALT sometime in Q4 when an unjustified sell-off occurs. As I predicted, after OWS vaccines (Moderna and Pfizer) received a stamp of approval from the FDA, ALT's price suffered a huge dip as retail investors rushed out. When that happened, each dip was bought up quickly in a few days. I think now is the time to accumulate ALT. In this article, I will explain why investors should consider buying ALT and why now.

For detailed information about Altimmune and its pipeline, please read my initiating coverage report that I have written in September. Altimmune: The Late Bloomer Of The COVID-19 Biotech World, The Best Is Yet To Come

Why is Altimmune a buying opportunity now?:

Strong COVID-19 and NASH pipeline, fundamental got better.

ALT has unique COVID19 vaccine programs that may prevent both infection and transmission by inducing sterilizing immunity.

AdCOVID's point of differentiation compared to OWS vaccines:

1. Only the intranasal route of administration can prevent both infection and transmission. This is because intranasal vaccines can induce mucosal immunity ((IgA)), which is imperative for reducing transmission.

2. Convenience: AdCOVID is a single dose vaccine that may be self-administrable. Patients may not need to visit a clinic, and the vaccine could be mailed to the patient's residence. This characteristic is well suited for children and senior patients.

3. AdCOVID is stable at room temperature for 3 months to 1 year and does not need a negative 30-70 degree cold chain like other OWS vaccines. This is well suited for developing countries and hot-climates.

4. Strong safety with mild side effects: AdCOVID and T-COVID haven't published results from the human studies yet, and the safety data is not available. However, we can use

Analyst’s Disclosure:I am/we are long ALT. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.